Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

ApTOLL for the Treatment of COVID-19

NCT05293236
completedphase_1

Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke

NCT04734548
completedphase_1

First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLL

NCT05569720
completedphase_1

First in Human Clinical Trial of ApTOLL in Healthy Volunteers

NCT04742062

Clinical Trials (4)

Showing 4 of 4 trials
NCT05293236Phase 1

ApTOLL for the Treatment of COVID-19

Terminated
NCT04734548Phase 1

Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke

Completed
NCT05569720Phase 1

First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLL

Completed
NCT04742062Phase 1

First in Human Clinical Trial of ApTOLL in Healthy Volunteers

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4